NASDAQ:BIVV Bioverativ (BIVV) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free BIVV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$104.98▼$104.9850-Day Range$104.98▼$104.9852-Week Range$48.14▼$105.01VolumeN/AAverage Volume3.03 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Bioverativ alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Bioverativ Stock (NASDAQ:BIVV)Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… BIVV Stock News HeadlinesMay 25, 2023 | morningstar.comBiogen Inc 0R1B Stock QuoteApril 1, 2023 | nasdaq.comEDU Crosses Above Average Analyst TargetApril 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. December 17, 2022 | thestreet.comBioverativ Makes Splash in Trading Debut, Gaining 18% on Day OneAugust 14, 2022 | seekingalpha.comAmarin Stock: Potential Risks And Rewards (NASDAQ:AMRN) - Seeking AlphaAugust 5, 2022 | marketscreener.comManagement to host conference call today at 4:30 p.m. ET - Form 8-K - Marketscreener.comAugust 4, 2022 | finance.yahoo.comCuris Reports Second Quarter 2022 Financial Results and Business Update - Yahoo FinanceJuly 28, 2022 | finance.yahoo.comPrime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio - Yahoo FinanceApril 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. July 28, 2022 | businesswire.comPrime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio - Business WireJuly 21, 2022 | law360.comChancery Holding Amplifies Approach To Boardroom Issues - Law360June 14, 2022 | finance.yahoo.comNeuron23 Appoints Kathy Dong, Pharm.D., MBA to Board of Directors - Yahoo FinanceMay 27, 2022 | law360.comNo Toss For Del. Suit Targeting $11.6B Sanofi-Bioverativ Deal - Law360April 28, 2022 | globenewswire.comPress Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1 - GlobeNewswireApril 4, 2022 | businesswire.comGlobal Next Generation Complement Therapeutics Market Report 2022-2035: Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, RoA - ResearchAndMarkets.com - Business WireApril 1, 2022 | prnewswire.comNuvalent Appoints Anna Protopapas as Chair of Board of Directors - PR NewswireMarch 31, 2022 | finance.yahoo.comNuvalent Appoints Anna Protopapas as Chair of Board of Directors - Yahoo FinanceMarch 30, 2022 | finance.yahoo.comCold Agglutinin Disease Market to Exhibit Massive Growth at a CAGR of 28% in the 7MM for the Study Period of 2019-32 | DelveInsight - Yahoo FinanceMarch 21, 2022 | businesswire.comWorldwide Gene Editing Beyond CRISPR Industry to 2035 - Featuring Amgen Ventures, ArrowMark Partners and Baxter Ventures Among Others - ResearchAndMarkets.com - Business WireMarch 19, 2022 | globenewswire.comHormone Refractory Prostate Cancer Market Size [2022-2028] - GlobeNewswireMarch 17, 2022 | finance.yahoo.comHormone Refractory Prostate Cancer Market Size [2022-2028] to Reach USD 18.35 Billion and Exhibit a CAGR of 9.64% | The Brainy Insights - Yahoo FinanceFebruary 22, 2022 | streetinsider.comSigilon Therapeutics (SGTX) Appoints Sarah Yuan as Chief Technical Operations Officer - StreetInsider.comJanuary 5, 2022 | finance.yahoo.comCrinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A. - Yahoo FinanceNovember 30, 2021 | prnewswire.comRemedium Bio appoints Dr. Alexey Seregin as Vice President of Research and Development - PRNewswireNovember 29, 2021 | streetinsider.comRemedium Bio appoints Dr. Alexey Seregin as Vice President of Research and Development - StreetInsider.comNovember 15, 2021 | forbes.comThe Billionaire Chairman Of Vaccine Maker Moderna Wants To Reinvent Scientific Entrepreneurship - ForbesOctober 12, 2021 | globenewswire.commRNA Synthesis and Manufacturing Services Market Report 2021-2030 - GlobeNewswireSee More Headlines Receive BIVV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioverativ and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/26/2017Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:BIVV CUSIPN/A CIK1681689 Webwww.bioverativ.com Phone+1-781-6634400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesBrian S. Posner (Age 55)Independent Chairman of the Board John G. Cox (Age 54)Chief Executive Officer, Director John T. Greene (Age 51)Chief Financial Officer, Executive Vice President, Treasurer Rogerio Vivaldi Coelho M.D. (Age 53)Executive Vice President, Chief Global Therapeutic Operations Officer Lucia Celona (Age 51)Executive Vice President, Chief Human Resources and Corporate Communications Officer Richard Brudnick (Age 60)Executive Vice President - Business Development Andrea Marie DiFabio (Age 48)Executive Vice President, Chief Legal Officer Diantha Duvall (Age 45)Vice President - Finance, Chief Accounting Officer Alexander J. Denner Ph.D. (Age 47)Independent Director Louis J. Paglia (Age 59)Independent Director More Executives BIVV Stock Analysis - Frequently Asked Questions How were Bioverativ's earnings last quarter? Bioverativ Inc. (NASDAQ:BIVV) issued its quarterly earnings data on Thursday, October, 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.25. The biotechnology company earned $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. Bioverativ's revenue for the quarter was up 27.2% on a year-over-year basis. What other stocks do shareholders of Bioverativ own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bioverativ investors own include Rexford Industrial Realty (REXR), Biogen (BIIB), Spark Therapeutics (ONCE), Marinus Pharmaceuticals (MRNS), Phillips 66 (PSX), Gilead Sciences (GILD), Verizon Communications (VZ), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN) and This page (NASDAQ:BIVV) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioverativ Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
